Twist Bioscience Corp (TWST) stock
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 13/30237% above fair value
$111.60−2.62 (-2.29%)
Close on Nov 13, 2026Market cap $7.00BP/E –Yield –
Twist Bioscience profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Twist Bioscience's profit margin for the twelve months ending Jun 30, 2026 was -31.7%. For fiscal 2025 it was -20.6%, against -66.7% the year before. The highest annual figure on record is -20.6% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -20.6% | +46.1 |
| FY2024 | Sep 30, 2024 | -66.7% | +16.8 |
| FY2023 | Sep 30, 2023 | -83.5% | +23.5 |
| FY2022 | Sep 30, 2022 | -107.0% | +7.9 |
| FY2021 | Sep 30, 2021 | -114.9% | +40.4 |
| FY2020 | Sep 30, 2020 | -155.3% | +42.7 |
| FY2019 | Sep 30, 2019 | -198.0% | +82.2 |
| FY2018 | Sep 30, 2018 | -280.2% | +270.7 |
| FY2017 | Sep 30, 2017 | -550.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -29.6% | −50.8 |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -39.8% | +2.6 |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -29.4% | +6.2 |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -27.4% | +13.5 |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | 21.2% | +126.3 |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -42.4% | +18.0 |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -35.6% | +24.5 |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -40.9% | +28.2 |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -105.0% | −15.0 |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -60.4% | +37.9 |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -60.2% | +17.0 |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -69.1% | +20.1 |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -90.0% | +17.8 |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -98.3% | +27.8 |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -77.1% | +31.3 |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -89.2% | +19.5 |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -107.8% | +6.5 |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -126.1% | −4.5 |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -108.4% | +8.4 |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -108.7% | −33.7 |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -114.3% | +18.7 |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -121.5% | +43.1 |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -116.8% | +207.3 |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -75.0% | +123.2 |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -133.0% | +72.3 |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -164.6% | +26.7 |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -324.2% | −127.2 |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -198.1% | +37.4 |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -205.3% | +64.2 |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -191.3% | +82.4 |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -197.0% | +195.7 |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -235.5% | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -269.4% | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -273.6% | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -392.7% | – |
See a number that looks wrong?